ERBB3 and breast carcinoma: Consistent with such a mechanism is the fact that both pertuzumab, which inhibits ErbB2/ErbB3 heterodimerization and signalling, and ALM are active preclinically against breast cancer cells that are not gene-amplified for ErbB2.